JP MORGAN CHASE-BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES‑02 Trial Advances and JPM Week Approaches

BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES‑02 Trial Advances and JPM Week Approaches

JP MORGAN CHASE(US:JPM) Businesswire·2026-01-06 13:45

ROOTSTOWN, Ohio--(BUSINESS WIRE)-- #Biotech--BioMendics advances its TAMES-02 trial of TolaSureâ"¢, a potential disease-modifying topical therapy for Epidermolysis Bullosa Simplex. ...